

1-11-03 Rec'd PCT PTO 10 JAN 2006

011006

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 7-2005)

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER
SERVIER 480 PCT

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/564137

INTERNATIONAL APPLICATION NO.
FR2004 001866

INTERNATIONAL FILING DATE
July 16, 2004

PRIORITY DATE CLAIMED
July 18, 2003

TITLE OF INVENTION
Orodispersible pharmaceutical composition of an antithrombotic compound.

APPLICANT(S) FOR DO/EO/US
Patrick WUTHRICH, Herve ROLLAND & Marc JULIEN

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- 1. ☒ This is a **FIRST** submission of items concerning a submission under 35 U.S.C. 371.
- 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a submission under 35 U.S.C. 371.
- 3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
- 4. ☐ The US has been elected (Article 31).
- 5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- 6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
- 7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
- 8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- 9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
- 10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
- 11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
- 12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 23 below concern document(s) or information included:

- 13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- 15. ☒ A **FIRST** preliminary amendment.
- 16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
- 17. ☐ A substitute specification.
- 18. ☒ A power of attorney and/or change of address letter.
- 19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
- 20. ☐ A second copy of the published International Application under 35 U.S.C. 154(d)(4).
- 21. ☐ A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).
- 22. ☒ Express Mail Label No. **EV 757927958 US**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

- a. ☒ A check in the amount of \$ \$1,000.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 08-3220. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

THE FIRM OF HUESCHEN AND SAGE
SEVENTH FLOOR, KALAMAZOO BUILDING
107 WEST MICHIGAN AVENUE
KALAMAZOO, MI 49007

CUSTOMER NUMBER: 25,666


SIGNATURE

G. PATRICK SAGE

NAME

37,710

REGISTRATION NUMBER

DATE

10 January 2006

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Patrick WUTHRIC, et al.

SERVIER 480 PCT

10/564137

Application No.

Filing Date

Examiner

Customer No.

Group Art Unit

Invention: Orodispersible pharmaceutical composition of an antithrombotic compound.

I hereby certify that the following correspondence:

Certified translation of International Patent Application PCT2004 001866 (9 pgs.), Transmittal Letter, Declaration / Power of Attorney, ISR, Form PTO 1449, Listing of claims, Preliminary Amendment, Certified copy of French Application 03.08780 and Translation thereof, and check no.74148 for \$1000.00

(Identify type of correspondence)


is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 10, 2006

(Date)

Linda Wooden

(Typed or Printed Name of Person Mailing Correspondence)



(Signature of Person Mailing Correspondence)

EV 757927958 US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.